Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis

被引：0
|
作者：
Knowles, Susan [1 ]
Taroumian, Sara [1 ]
Lisse, Jeffrey R. [1 ]
Yanes, James [1 ]
Ampel, Neil M. [2 ]
Gall, Eric P. [3 ]
Grau, Rafael G. [1 ]
Bode, Barbara Y. [2 ]
Vaz, Berchman A. [4 ]
Galgiani, John [5 ]
Hoover, Susan E. [1 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] So AZ VA Med Ctr, Tucson, AZ USA
[3] Arizona Arthrit Ctr, Tucson, AZ USA
[4] Catalina Pointe Arthrit & Rheumatol, Tucson, AZ USA
[5] Valley Fever Ctr Excellence, Tucson, AZ USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2466
引用
收藏
页码：S961 / S961
页数：1
相关论文
共 50 条
  • [21] Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
    Yinzhu Jin
    Rishi J. Desai
    Jun Liu
    Nam-Kyong Choi
    Seoyoung C. Kim
    Arthritis Research & Therapy, 19
  • [22] SAFETY AND EFFECTIVENESS OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITI
    Freitas, Raquel
    Fonseca, Joao Eurico
    Polido-Pereira, Joaquim
    Madeira, Nathalie
    Miranda, Luis Cunha
    Bernardes, Miguel
    Fernandes, Bruno Miguel
    Costa, Flavio
    Santiago, Mariana
    Neto, Agna
    Azevedo, Soraia
    Dias, Joao Madruga
    Couto, Mara
    Sequeira, Graca
    Santos, Maria Jose
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1142 - 1143
  • [23] Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    Hosseini, Roya
    Fawaz, Souhiela
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2595 - 2595
  • [24] FACTORS ASSOCIATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS UTILIZATION IN RHEUMATOID ARTHRITIS PATIENTS
    Hosseini, R.
    Brown, L.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2022, 25 (07) : S453 - S453
  • [25] Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung C.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [26] Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Hosseini, Roya
    Brown, Lawrence
    Fleming, Marc
    Rodriguez-Monguio, Rosa
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2161 - 2162
  • [27] Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma
    Calip, Gregory S.
    Patel, Pritesh R.
    Sweiss, Karen
    Wu, Zhaoju
    Zhou, Jifang
    Asfaw, Alemseged A.
    Adimadhyam, Sruthi
    Lee, Todd A.
    Chiu, Brian C-H
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (05) : 1300 - 1305
  • [28] Modern disease-modifying antirheumatic drugs
    Mueller-Ladner, U.
    Richter, K.
    Tarner, I. H.
    INTERNIST, 2015, 56 (03): : 307 - 314
  • [29] The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States
    Ding, Qian
    Shiltz, Dane
    Hossami, Dana
    Konieczny, Alison M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (08) : 1231 - 1241
  • [30] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC AND NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 374 - 375
12345